Treatment for Neuroendocrine Tumors

Phase-Based Progress Estimates
1
Effectiveness
1
Safety
Princess Margaret Cancer Centre, Toronto, CanadaNeuroendocrine Tumors
Eligibility
18+
All Sexes
What conditions do you have?
Select

Study Summary

This trial will help determine if a correlation exists between how a tumor looks on a DT PET scan and how aggressive it is.

Treatment Effectiveness

Effectiveness Progress

1 of 3

Study Objectives

2 Primary · 3 Secondary · Reporting Duration: 2 years

2 years
Discordance in tracer uptake
Impact to patient management
Intraindividual tumor heterogeneity
Tumor texture features as predictors of tumor metabolism and somatostatin receptor expression
Tumor texture geatures as predictors of tumor grade

Trial Safety

Safety Progress

1 of 3

Trial Design

0 Treatment Group

40 Total Participants · 0 Treatment Group

Primary Treatment: Treatment · No Placebo Group · N/A

Trial Logistics

Trial Timeline

Screening: ~3 weeks
Treatment: Varies
Reporting: 2 years

Who is running the clinical trial?

University Health Network, TorontoLead Sponsor
1,386 Previous Clinical Trials
471,954 Total Patients Enrolled
4 Trials studying Neuroendocrine Tumors
2,230 Patients Enrolled for Neuroendocrine Tumors
Ur Metser, MDPrincipal InvestigatorUniversity Health Network, Toronto
6 Previous Clinical Trials
739 Total Patients Enrolled

Eligibility Criteria

Age 18+ · All Participants · 9 Total Inclusion Criteria

Mark “Yes” if the following statements are true for you:

Frequently Asked Questions

Is there an opportunity for individuals to join the experiment?

"Based on the information provided by clinicaltrials.gov, this study is still enrolling patients as of May 20th 2022. The trial was initially launched in March 4th 2021." - Anonymous Online Contributor

Unverified Answer

What other investigations have been conducted surrounding this therapy?

"Currently, 18 studies are being conducted in relation to this treatment. One is at the pivotal Phase 3 stage and 19 different sites across Wuhan, Hubei province are running tests on it." - Anonymous Online Contributor

Unverified Answer

What conditions can this particular remedy ameliorate?

"This pharmaceutical is typically used to manage seizures, but it has also been demonstrated as a viable option for treating coronary artery disease (CAD), cancer, and positron emission tomography." - Anonymous Online Contributor

Unverified Answer

What is the current enrollment of this clinical research endeavor?

"Affirmative. According to clinicaltrials.gov, this research is actively enrolling participants; it was first published on March 4th 2021 and the most recent update occurred on May 20th 2022. The study requires 40 individuals from one medical site." - Anonymous Online Contributor

Unverified Answer
Please Note: These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.